Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Lanabecestat and CYP3A Substrates in Healthy Subjects
NCT02406261Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lanabecestat in Alzheimer's disease (AD) (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve Zero to Infinity (AUC[0-∞]) for LY3314814 at Day 4, Area Under the Curve Zero to Infinity (AUC[0-∞]) for Simvastatin at Day 36 and 2 more. Started Apr 2015; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02406261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406261.